[1]
Sun, M.R.; Li, H.L.; Ba, M-Y.; Cheng, W.; Zhu, H-L.; Duan, Y-T. Cyclopropyl scaffold: A generalist for marketed drugs. Mini Rev. Med. Chem., 2021, 21(2), 150-170.
[2]
Duan, Y.; Liu, W.; Tian, L.; Mao, Y.; Song, C. Targeting Tubulin-colchicine site for cancer therapy: Inhibitors, antibody- drug conjugates and degradation agents. Curr. Top. Med. Chem., 2019, 19(15), 1289-1304.
[3]
Zhao, L.; Duan, Y.T.; Lu, P. Zhang, Z-J.; Zheng, X-K.; Wang, J-L.; Feng, W-S. Epigenetic targets and their inhibitors in cancer therapy. Curr. Top. Med. Chem., 2018, 18(28), 2395-2419.
[4]
Wang, Y.; Sun, M.; Wang, Y.; Qin, J.; Zhang, Y.; Pang, Y.; Yao, Y.; Yang, H.; Duan, Y. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency. Eur. J. Med. Chem., 2021, 225, 113790
[5]
Sun, M.; Wang, Y.; Yuan, M.; Zhao, Q.; Zhang, Y.; Yao, Y.; Duan, Y. Angiogenesis, anti-tumor, and anti-metastatic activity of novel α-substituted hetero-aromatic chalcone hybrids as inhibitors of microtubule polymerization. Front Chem., 2021, 9, 766201
[6]
Xia, D.; Liu, H.; Cheng, X.; Maraswami, M.; Chen, Y.; Lv, X. Recent developments of coumarin-based hybrids in drug discovery. Curr. Top. Med. Chem., 2022, 22(4), 269-283.